Mpoudi-Ngole E - Search Results

1

Striking lack of T cell immunodominance in both a multiclade and monoclade HIV-1 epidemic: implications for vaccine development.

Tongo M, Zembe L, Ebong E, Roux S, Bekker LG, Williamson C, Mpoudi-Ngole E, Burgers WA. Tongo M, et al. Vaccine. 2014 Apr 25;32(20):2328-36. doi: 10.1016/j.vaccine.2014.02.063. Epub 2014 Mar 2. Vaccine. 2014. PMID: 24598726

2

Coronaviruses Are Abundant and Genetically Diverse in West and Central African Bats, including Viruses Closely Related to Human Coronaviruses.

Meta Djomsi D, Lacroix A, Soumah AK, Kinganda Lusamaki E, Mesdour A, Raulino R, Esteban A, Ndong Bass I, Mba Djonzo FA, Goumou S, Ndimbo-Kimugu SP, Lempu G, Mbala Kingebeni P, Bamuleka DM, Likofata J, Muyembe Tamfum JJ, Toure A, Mpoudi Ngole E, Kouanfack C, Delaporte E, Keita AK, Ahuka-Mundeke S, Ayouba A, Peeters M. Meta Djomsi D, et al. Among authors: mpoudi ngole e. Viruses. 2023 Jan 25;15(2):337. doi: 10.3390/v15020337. Viruses. 2023. PMID: 36851551 Free PMC article.

3

Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon.

Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Atem-Tambe A, Tongo M, Butel C, Delaporte E, Peeters M. Aghokeng AF, et al. PLoS One. 2009 Nov 6;4(11):e7702. doi: 10.1371/journal.pone.0007702. PLoS One. 2009. PMID: 19893738 Free PMC article.

4

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M. Aghokeng AF, et al. AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9. AIDS. 2011. PMID: 21860346

5

Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.

Jacob RA, Abrahams F, Tongo M, Schomaker M, Roux P, Mpoudi Ngole E, Burgers WA, Dorfman JR. Jacob RA, et al. J Virol. 2012 Jul;86(14):7699-703. doi: 10.1128/JVI.00804-12. Epub 2012 May 9. J Virol. 2012. PMID: 22573859 Free PMC article.

6

Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic.

Tongo M, Martin DP, Zembe L, Mpoudi-Ngole E, Williamson C, Burgers WA. Tongo M, et al. Virol J. 2013 Jan 22;10:29. doi: 10.1186/1743-422X-10-29. Virol J. 2013. PMID: 23339631 Free PMC article.

7

Evaluating potential T-cell epitope peptides for detecting HIV-specific T cell responses in a highly diverse HIV-1 epidemic from Cameroon.

Tongo M, Riou C, Crunchant E, Müller TL, Strickland N, Mpoudi-Ngole E, Burgers WA. Tongo M, et al. AIDS. 2015 Mar 13;29(5):635-639. doi: 10.1097/QAD.0000000000000581. AIDS. 2015. PMID: 25715106 Free PMC article.

8

Phylogenetics of HIV-1 subtype G env: Greater complexity and older origins than previously reported.

Tongo M, Essomba RG, Nindo F, Abrahams F, Nanfack AJ, Fokam J, Takou D, Torimiro JN, Mpoudi-Ngole E, Burgers WA, Martin DP, Dorfman JR. Tongo M, et al. Infect Genet Evol. 2015 Oct;35:9-18. doi: 10.1016/j.meegid.2015.07.017. Epub 2015 Jul 17. Infect Genet Evol. 2015. PMID: 26190450

9

Near full-length HIV type 1M genomic sequences from Cameroon : Evidence of early diverging under-sampled lineages in the country.

Tongo M, Dorfman JR, Abrahams MR, Mpoudi-Ngole E, Burgers WA, Martin DP. Tongo M, et al. Evol Med Public Health. 2015 Sep 9;2015(1):254-65. doi: 10.1093/emph/eov022. Evol Med Public Health. 2015. PMID: 26354000 Free PMC article.

10

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.

Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngolé E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Calmy A, et al. Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1. Lancet HIV. 2020. PMID: 33010241 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters